Target Price (Mid): ~$27Street Target: ~$31Potential Total Return: ~(13%)Annualized IRR: ~(3%) / yearWhat Happened?Hims & ...
Hims & Hers Health has been a dramatic ride for shareholders over the past few years, yet recent share price weakness now has ...
Suppose improving growth and profitability allow investors to value the company at 2.5x expected 2027 sales. Applying that multiple to the $3.99 billion revenue estimate produces a market ...
Zacks Investment Research on MSN
Hims & Hers Health, Inc. (HIMS) is attracting investor attention: Here is what you should know
Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
Cencora stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing.
Zacks Investment Research on MSN
Hims & Hers expands Australian women's health platform with Hers
Hims & Hers Health HIMS recently announced the launch of Hers, its women's health platform, in Australia. The launch rebrands ...
Hims & Hers and Novo Nordisk have had a tumultuous relationship over the past couple of years. The companies formed a short-lived commercial partnership last year, only for Novo Nordisk to walk away, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results